Zacks Research Forecasts TSE:ONC FY2026 Earnings

Oncolytics Biotech Inc. (TSE:ONC) – Stock analysts at Zacks Research issued their FY2026 EPS estimates for shares of Oncolytics Biotech in a report released on Tuesday, April 7th. Zacks Research analyst D. Bautz anticipates that the company will post earnings of ($0.33) per share for the year. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Zacks Research also issued estimates for Oncolytics Biotech’s FY2027 earnings at ($0.32) EPS and FY2028 earnings at ($0.29) EPS.

Oncolytics Biotech Price Performance

Shares of Oncolytics Biotech stock opened at C$14.90 on Wednesday. The company has a debt-to-equity ratio of 14.58, a quick ratio of 8.86 and a current ratio of 2.88. The firm’s 50-day simple moving average is C$14.90 and its 200-day simple moving average is C$14.90. Oncolytics Biotech has a twelve month low of C$0.44 and a twelve month high of C$2.08. The firm has a market cap of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80.

Insiders Place Their Bets

In related news, Director Bernd Robert Seizinger bought 60,000 shares of the company’s stock in a transaction dated Wednesday, February 11th. The stock was acquired at an average cost of C$1.14 per share, with a total value of C$68,400.00. Following the acquisition, the director owned 526,991 shares in the company, valued at approximately C$600,769.74. This represents a 12.85% increase in their position. Also, Director Patricia Andrews bought 35,400 shares of the company’s stock in a transaction dated Thursday, February 12th. The stock was bought at an average cost of C$1.18 per share, with a total value of C$41,772.00. Following the completion of the acquisition, the director owned 78,128 shares in the company, valued at C$92,191.04. This represents a 82.85% increase in their position. Insiders acquired a total of 289,232 shares of company stock worth $335,760 in the last 90 days. 3.82% of the stock is owned by corporate insiders.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.